Medios achieves double-digit revenue growth and improves profitability

Press release

Medios achieves double-digit revenue growth and improves profitability

• Consolidated revenue increased to €2.1 billion (+10.4%)
• EBITDA pre¹ rose disproportionately by 17.8%
• EBITDA pre¹ margin increased to 4.5% (previous year: 4.2%)
• Earnings per share increased significantly to €0.61 (previous year: €0.51)
• Outlook for 2026: Revenue expected to be between €2.0 billion and €2.12 billion – with a further improvement in the EBITDA pre¹ margin to around 4.8%

Berlin, March 26, 2026 – The Medios-Group (“Medios“), a leading provider of Specialty Pharma in Europe, has published its 2025 annual report. Consolidated revenue increased by 10.4% year-over-year to €2.1 billion (previous year: €1.9 billion). EBITDA pre¹ rose significantly by 17.8% to €93.1 million (previous year: €79.0 million). Revenue and EBITDA pre¹ are thus broadly in line with the forecast. The EBITDA pre¹ margin improved accordingly to 4.5% (previous year: 4.2%). The Pharmaceutical Supply segment and the International Business segment, which has been part of the Group since June 2024, were the main contributors to this development. Organic growth in revenue and EBITDA pre¹ reached 7.0% and 2.7%, respectively. Consolidated net income after income taxes rose by 22.4% to €15.4 million (previous year: €12.5 million), resulting in an increase in earnings per share to €0.61 (previous year: €0.51).

All operating segments contributed to the increase in revenue
In the Pharmaceutical Supply segment, external revenue rose by 6.9% in the 2025 financial year to €1,688.8 million (previous year: €1,580.0 million). EBITDA pre¹ rose by 5.1% to €52.5 million (previous year: €50.0 million).

The Patient-Specific Therapies segment generated external revenue of €220.1 million (previous year: €213.6 million), representing a slight increase of 3.0%. EBITDA pre¹, however, fell by 4.6% to €22.2 million (previous year: €23.3 million).

The International Business segment made a significant contribution to the Medios Group’s positive performance in the 2025 financial year, with external revenue of €169.2 million (June to December 2024: €88.8 million) and EBITDA pre¹ of €29.1 million (June to December 2024: €16.3 million).

Further margin growth expected in the 2026 financial year
In 2026, Medios will focus on operational excellence, the harmonization of key business processes, the expansion of organic growth, and selective acquisitions.

For the 2026 financial year, the Medios Group expects revenue of €2.0 billion to €2.12 billion and EBITDA pre¹ of €94 million to €102 million. This would correspond to a further increase in the EBITDA pre¹ margin to approximately 4.8%.

The 2025 Annual Report is available for download on the Investor Relations website.

Important events for the Medios Group in the 2026 financial year:

-------------------

About Medios AG
Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany's first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group

More information on individualized medicine: https://app.medios.group/en/individualizedmedicine

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
[email protected]
www.medios.ag

Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.